Choy E, et al. - Researchers performed a pooled analysis of the TOZURA study programme in order to gain insight into the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response to csDMARD or anti-TNF agent therapy or who were MTX naïve. Findings provided corroboration for the known efficacy and safety profile of TCZ-SC in this population, with comparable effects as monotherapy and in combination with csDMARDs.